Avient
AVIENT CORPORATION
Key figures
Period Jan 2025 to Dec 2025ConsolidatedU.S. GAAP
RevenueDisclosed
US$3.3B
Operating marginCalculated
6.2%
Net assets to total assetsCalculated
39.4%
Company profile
Tables scroll sideways
Disclosed data
Profitability
★★☆☆☆position among all companies
6.2%
Growth (revenue, 4-year average)
★☆☆☆☆position among all companies
-0.4%
Capital efficiency
★★☆☆☆position among all companies
3.4%
Revenue and profit
Performance, financial position and capital allocation
Avient
Recent performance trends
Avient
Cash flow trends
Consolidated indicators (9 items)
| Item | 4 years ago | 3 years ago | 2 years ago | Last year | This year |
|---|---|---|---|---|---|
| Net sales | US$3.3 billion | US$3.4 billion | US$3.1 billion | US$3.2 billion | US$3.3 billion |
| Operating income | US$0.3 billion | US$0.2 billion | US$0.2 billion | US$0.3 billion | US$0.2 billion |
| Net income | US$0.2 billion | US$0.7 billion | US$75.70 million | US$0.2 billion | US$81.90 million |
| Total assets | US$5.0 billion | US$6.1 billion | US$6.0 billion | US$5.8 billion | US$6.0 billion |
| Shareholders' equity | US$1.8 billion | US$2.3 billion | US$2.3 billion | US$2.3 billion | US$2.4 billion |
| Net cash provided by (used in) operating activities | US$0.2 billion | US$0.4 billion | US$0.2 billion | US$0.3 billion | US$0.3 billion |
| Net cash provided by (used in) investing activities | US$-0.2 billion | US$-0.5 billion | US$-94.20 million | US$-0.1 billion | US$-97.00 million |
| Net cash provided by (used in) financing activities | US$-0.1 billion | US$0.2 billion | US$-0.2 billion | US$-0.1 billion | US$-0.3 billion |
| Cash and cash equivalents | US$0.6 billion | US$0.6 billion | US$0.5 billion | US$0.5 billion | US$0.5 billion |
Revenue scale in the same industry
Avient
Chemicals and pharmaceuticals: 56 companies · revenue · largest first・each company’s latest fiscal year・Consolidated・Disclosed
- 1 Johnson & JohnsonFY Dec 2025 US$94.2B
- 2 Procter & GambleFY Jun 2026 US$87.0B
- 3 ELI Lilly ANDFY Dec 2025 US$65.2B
- … 48 companies
- 52 FMCFY Dec 2025 US$3.5B
- 53 Scotts Miracle-GroFY Sep 2025 US$3.4B
- 54 AvientThis companyFY Dec 2025 US$3.3B
- 55 Biomarin PharmaceuticalFY Dec 2025 US$3.2B
- 56 United TherapeuticsFY Dec 2025 US$3.2B
Sources and methodology
Basic indicators
| Item | Value | Consolidated / Non-consolidated | Source |
|---|---|---|---|
| Purchase of property, plant and equipment | US$0.1 billion | Consolidated | Disclosed |
| Cash and cash equivalents | US$0.5 billion | Consolidated | Disclosed |
| Net cash provided by (used in) financing activities | US$-0.3 billion | Consolidated | Disclosed |
| Net cash provided by (used in) investing activities | US$-97.00 million | Consolidated | Disclosed |
| Net cash provided by (used in) operating activities | US$0.3 billion | Consolidated | Disclosed |
| Depreciation and amortization | US$0.2 billion | Consolidated | Disclosed |
| Dividends paid | US$98.80 million | Consolidated | Disclosed |
| Stockholders' equity (including non-controlling interests) | US$2.4 billion | Consolidated | Disclosed |
| Non-controlling interests | US$12.10 million | Consolidated | Disclosed |
| Net assets | US$2.4 billion | Consolidated | Disclosed |
| Net sales | US$3.3 billion | Consolidated | Disclosed |
| Operating income | US$0.2 billion | Consolidated | Disclosed |
| Net income | US$81.90 million | Consolidated | Disclosed |
| Total assets | US$6.0 billion | Consolidated | Disclosed |
| Operating margin | 6.2% | Consolidated | Calculated |
| Net assets to total assets | 39.4% | Consolidated | Calculated |
| Net margin | 2.5% | Consolidated | Calculated |
| Return on equity | 3.4% | Consolidated | Calculated |